Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank54
3Y CAGR+69.4%
5Y CAGR+5.9%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+69.4%/yr
vs -41.7%/yr prior
5Y CAGR
+5.9%/yr
Recent acceleration
Acceleration
+111.1pp
Accelerating
Percentile
P54
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1.75 | -29.9% |
| 2024 | 2.50 | +109.5% |
| 2023 | 1.19 | +231.2% |
| 2022 | 0.36 | -79.7% |
| 2021 | 1.77 | +34.7% |
| 2020 | 1.32 | -41.1% |
| 2019 | 2.23 | -28.2% |
| 2018 | 3.11 | -14.4% |
| 2017 | 3.63 | -98.6% |
| 2016 | 255.79 | - |